Key Takeaways
- Spain’s medical cannabis system is transitioning from legal approval to actual procurement, with hospitals beginning to order standardized cannabis preparations.
- Curaleaf’s products CAN-1 and CAN-2 now appear on the AEMPS register, but patient access remains unclear as no patients have been treated yet.
- Only specific conditions qualify for treatment, such as refractory epilepsy and chronic pain, with prescriptions limited to hospital specialists.
- The rollout hinges on individual hospital pharmacies’ ability to compound and dispense cannabis formulations effectively.
- Data on patient treatment is essential to evaluate the system’s success, moving beyond just tracking hospital orders.
A year after Spain’s government approved Royal Decree 903/2025, the paperwork phase of medical cannabis is finally giving way to actual procurement. El País reports that Spanish hospitals have started placing orders for standardized cannabis preparations, with Curaleaf planning its first deliveries to around 50 public and private facilities this week.
Curaleaf’s two products, CAN-1 (CBD-dominant) and CAN-2 (THC-dominant), are listed on the AEMPS register of standardized cannabis preparations. Curaleaf CEO Juan Pablo Martínez told El País the company expects a gradual rollout as more hospitals request the product.
It’s worth being precise about what’s actually happened so far. Orders and shipments mean hospitals are building supply chains. They don’t mean patients are being treated yet. No named patient has been publicly confirmed as receiving a cannabis-based formulation through this pathway, and there’s no public data yet on how many prescriptions have actually been filled.
That distinction matters for anyone trying to gauge how this rollout is going. A company announcing 50 hospital partners is a distribution milestone, not a clinical one. The real test of Spain’s new system will be measured in patients treated, not purchase orders placed.
Why Did It Take a Year to Go from Registration to Hospital Orders?
The clock started last year in October, when Spain’s Council of Ministers approved Royal Decree 903/2025, opening a hospital-only pathway for cannabis-based treatment prescribed by specialists. According to the European Observatory on Health Systems and Policies, the decree tasked AEMPS with setting clinical indications, preparation standards, dosing rules, and prescription conditions, along with a public registry and ongoing effectiveness monitoring shared between prescribing physicians and hospital pharmacies.
That groundwork took months. AEMPS approved the first compounds over the summer of 2026. Business of Cannabis reported in July that Curaleaf, through its Alicante-based subsidiary Medalchemy, became the first company to register preparations under the new framework. As of mid-2026, only four companies held AEMPS cultivation licenses in Spain, a bottleneck that limited how quickly supply could scale.
Even after registration, confusion slowed things further. El País reports that AEMPS clarified last week that hospitals do not need a separate new authorization before ordering registered preparations. Some hospital pharmacies were mistakenly waiting for one, according to agency sources. With that clarified, the rollout now depends entirely on individual hospital management teams choosing to start dispensing.
In short: the legal infrastructure is built. What happens next depends on hospital administrators, not regulators.
Which Conditions Qualify for Standardized Cannabis Preparations in Spain?
Access isn’t open-ended. Under the national formulary entry for this preparation, standardized cannabis solutions are classified as last-line treatment, meaning doctors can only prescribe them after other approved medications have failed to adequately help a patient.
El País outlines four qualifying conditions: spasticity associated with multiple sclerosis, severe forms of refractory epilepsy, nausea and vomiting caused by chemotherapy, and chronic pain that hasn’t responded to other treatments. Chronic pain is expected to be the largest category by patient volume, though there’s no official estimate yet of how many of Spain’s nine million chronic pain sufferers might qualify.
Prescribing is restricted to hospital specialists, mainly oncologists, hematologists, anesthesiologists, and pain medicine physicians, who must evaluate each patient individually and document that other options, including opioids, have already failed. Only hospital pharmacies can dispense the formulations. There’s no retail or community pharmacy access, and no smokeable flower option; this pathway covers oral solutions only.
The official monograph also carries substantial warnings, covering drug interactions, psychiatric risk, pregnancy and lactation contraindications, sedation, and driving impairment. These aren’t minor footnotes. Spain’s approach treats cannabis as a carefully fenced-in option for patients who’ve run out of other choices, not a first-line therapy.
How Will Hospital Pharmacies Prepare and Dispense CAN-1 and CAN-2?
The process is more pharmacy science than retail transaction. Ana María Martín of the compounding group at the Spanish Society of Hospital Pharmacy (SEFH) told El País that the raw extracts are high concentration, and each formula gets individualized based on the patient’s clinical situation, existing medications, and tolerance.
In practice, hospital pharmacists receive CAN-1 (CBD-dominant) and CAN-2 (THC-dominant) separately, then translate a physician’s clinical order into a specific THC-to-CBD ratio for that patient. The national formulary entry for this preparation describes a defined compounding method: weighing out each extract, blending them with medium-chain triglycerides as a carrier, mixing until fully homogenized, then bottling in amber glass with a dosing cap.
Traceability is built into the requirement. Pharmacies must track which batch and ratio went to which patient, partly because dosing starts low and gets adjusted gradually. The formulary caps adult THC intake at 32.4 mg daily, with separate pediatric limits that vary by indication.
This individualized compounding model explains some of the rollout’s slow pace. It’s not like shipping a standardized pill bottle. Each hospital pharmacy needs staff trained in this specific process, and that training takes time to roll out across even 50 facilities, let alone the hundreds of hospitals across Spain’s regional health systems.
What Do Doctors and Patients Say About This Rollout?
Reactions from clinicians are cautiously hopeful rather than celebratory. Carlos Tornero, who leads the pain unit at Hospital Clínico Universitario Valencia and sits on the pain section of Spain’s anesthesiology society (SEDAR), told El País the goal is improving quality of life, function, pain levels, and sleep, not eliminating pain entirely. He also stressed these treatments need to fit into a broader plan that includes physical therapy, exercise, and other medications, while carefully screening for substance use disorders, schizophrenia, or bipolar disorder.
Ana Blasco of the Spanish Society of Medical Oncology (SEOM) added a note of scientific caution. She said some studies show improvement in refractory pain with THC and CBD combinations, but with low certainty, and there’s moderate evidence that oral THC doesn’t help patients whose severe pain hasn’t responded to opioids. Many existing studies compare patients only to their own prior symptoms, which makes it hard to separate real drug effects from placebo or natural symptom fluctuation.
For patients, the stakes are higher. Carola Pérez, president of the Observatorio Español de Cannabis Medicinal and a chronic neuropathic pain patient herself, described the shift to El País: finally stepping away from reliance on black market suppliers. She’s tried neurostimulators, intravenous ketamine, fentanyl, and methadone without lasting relief, and hopes this new system offers something she hasn’t had: a standardized product with controlled dosing and clinical supervision, inside the regulated system rather than outside it.
What Should We Watch for Next?
The milestone is procurement, not treatment. Measuring whether Spain’s system actually works will require tracking several things over the coming months:
- Which hospitals actually place orders beyond Curaleaf’s initial 50, and which regions lag behind
- Which hospital pharmacies successfully compound and dispense formulations, versus those that ordered but stalled
- Which conditions patients are actually being treated for, and in what proportions
- How long patients wait between a specialist’s prescription and receiving their first dose
- Whether patients face out-of-pocket costs, since Business of Cannabis has stated Spanish patients won’t pay for hospital-dispensed prescriptions, though El País’s reporting didn’t independently confirm this detail in practice
- How consistently adverse events get reported and reviewed across different hospital systems
- Whether regional health budgets reimburse these formulations evenly, or whether some regions effectively ration access
That last point carries real risk. A rollout spanning 50 hospitals sounds impressive on a press release, but it could just as easily produce uneven access hidden behind a good headline number, depending on how individual hospital budgets, specialist confidence, and regional health policies play out.
Spain’s Cannabis System Now Needs Patients, Not Paperwork
Spain spent a full year building the legal machinery for medical cannabis: a royal decree, an AEMPS registry, approved formulations, and a defined compounding process. That infrastructure is now in place. What’s missing is proof that it actually reaches the patients it was built for.
Counting hospitals that received shipments this week tells us distribution is starting. It doesn’t tell us whether a multiple sclerosis patient in Galicia gets the same access as one in Madrid, whether chronic pain patients actually get prescriptions after months of failed alternatives, or whether adverse events get caught and reported consistently.
The next useful milestone isn’t another list of participating hospitals. It’s the first independently verified count of patients actually treated, broken down by condition and region. Until that data exists, Spain’s medical cannabis program remains a well-built system waiting to prove it works.
Frequently Asked Questions
Yes, but only through a narrow hospital pathway. Under Royal Decree 903/2025, specialist physicians in Spanish hospitals can prescribe standardized cannabis preparations for specific refractory conditions, and only hospital pharmacies can dispense them. There’s no general prescription, retail, or recreational access tied to this framework.
Patients qualify only if they have one of four conditions and haven’t responded to other treatments: spasticity from multiple sclerosis, severe refractory epilepsy, chemotherapy-induced nausea and vomiting, or chronic pain unresponsive to other therapies. A hospital specialist must evaluate each case individually and document that other options, including opioids, have already failed.
This remains unconfirmed in practice. Business of Cannabis has reported that patients don’t pay out of pocket for prescriptions dispensed through hospital pharmacies, but El País’s reporting on this week’s rollout didn’t include independent cost data, so this detail still needs real-world confirmation as prescriptions begin.
CAN-1 and CAN-2 are the first two standardized cannabis preparations registered with AEMPS, Spain’s medicines agency, both developed by Curaleaf’s Spanish subsidiary, Medalchemy. CAN-1 is CBD-dominant and CAN-2 is THC-dominant. Hospital pharmacies combine the two in individualized ratios based on each patient’s prescribed formula.
There’s no fixed timeline. Curaleaf expects deliveries to around 50 hospitals this week, with a gradual expansion as more facilities request the product. Actual patient access depends on individual hospital pharmacies completing compounding training and specialist physicians writing prescriptions, so timelines will likely vary significantly by hospital and region.
